OTCPK:NWCI

Stock Analysis Report

Executive Summary

NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has NewCardio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NWCI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

NWCI

4.9%

US Healthcare Services

9.4%

US Market


1 Year Return

-47.5%

NWCI

15.5%

US Healthcare Services

-6.8%

US Market

Return vs Industry: NWCI underperformed the US Healthcare Services industry which returned 12.5% over the past year.

Return vs Market: NWCI underperformed the US Market which returned -8.1% over the past year.


Shareholder returns

NWCIIndustryMarket
7 Day0%4.9%9.4%
30 Day60.8%0.9%-3.9%
90 Day-30.1%-0.06%-16.5%
1 Year-47.5%-47.5%15.9%15.5%-4.8%-6.8%
3 Year318.0%318.0%71.2%70.3%23.4%15.2%
5 Year248.3%248.3%51.3%49.9%41.3%25.7%

Price Volatility Vs. Market

How volatile is NewCardio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NewCardio undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether NewCardio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NewCardio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of NWCI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through NewCardio regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is NewCardio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NewCardio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of NWCI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access NewCardio's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has NewCardio performed over the past 5 years?

20.6%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, NewCardio has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at NewCardio's' management and board experience and expertise to assess their ability to deliver on their strategic promises.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access NewCardio's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is NewCardio's financial position?


In this section we usually analyse NewCardio's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. NewCardio has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of NWCI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when NewCardio's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is NewCardio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NWCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NWCI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NWCI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NWCI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NWCI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.5yrs

Average board tenure


CEO

Jess Jones (40yo)

8.25s

Tenure

Dr. Jess Emery Jones, M.D. has been the Chief Executive Officer of NewCardio, Inc. since January 1, 2012. Dr. Jones serves as a Director of Healthcare Investing at Vision Capital Advisors, LLC. He serves a ...


Board Members

NamePositionTenureCompensationOwnership
Jess Jones
CEO & Director8.25yrsno datano data
Craig Pratt
Member of Scientific Advisory Board12.08yrsno datano data
Peter Kowey
Member of Scientific Advisory Board11.75yrsno datano data
Mark Josephson
Chairman of Scientific Advisory Boardno datano datano data
Phillip Sager
Member of Scientific Advisory Board11.33yrsno datano data

11.5yrs

Average Tenure

Experienced Board: NWCI's board of directors are seasoned and experienced ( 11.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

NewCardio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NewCardio, Inc.
  • Ticker: NWCI
  • Exchange: OTCPK
  • Founded: 2004
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$85.287k
  • Shares outstanding: 40.81m
  • Website: https://null

Number of Employees


Location

  • NewCardio, Inc.
  • PO Box 658
  • Branchburg
  • New Jersey
  • 8853
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NWCIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2006

Biography

NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company’s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 00:13
End of Day Share Price2020/03/25 00:00
Earnings2011/09/30
Annual Earnings2010/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.